Semaglutide及Tirzepatide肽原料藥CDMO市場機會、成長驅動因子、產業趨勢分析及2026-2035年預測

全球Semaglutide和Tirzepatide原料藥CDMO市場預計到2025年價值15億美元，預計到2035年將以15.2%的複合年成長率成長至67億美元。

由於全球對胜肽療法的需求不斷成長，以及針對慢性代謝疾病的先進療法的商業化，該市場正在快速擴張。將原料藥(API) 的生產外包給專業的合約研發生產機構 (CDMO) 的趨勢日益成長，為行業相關人員創造了巨大的成長機會。製藥公司越來越依賴經驗豐富的生產合作夥伴來提高產能、最佳化成本、縮短產品開發週期並確保符合監管要求。對胜肽合成技術、製程最佳化和大規模生產基礎設施的投資增加，進一步推動了市場成長。此外，慢性疾病盛行率的上升、生物製藥產品線的擴展以及對高品質藥物生產的日益重視，都持續增強了對專業 API 生產服務的需求。胜肽生產、品質保證和製程可擴展性方面的持續技術進步，使 CDMO 能夠滿足客戶不斷變化的需求。隨著全球製藥業創新步伐的不斷加快，預計Semaglutide和TirzepatideAPI CDMO 市場將在整個預測期內保持強勁成長。

預計到2025年，Semaglutide市佔率將達到58.7%，並在2026年至2035年間以14.8%的複合年成長率成長。其主導的市場地位得益於廣泛的商業性應用、成熟的全球生產生態系統以及針對代謝健康療法的日益成長的需求。患者接受度的持續提高、生產需求的增加以及生產外包的增加，正在推動對Semaglutide肽原料藥開發和生產服務的需求。合約研發生產機構（CDMO）正在投資先進的胜肽原料藥技術、擴大產能並最佳化工藝，以滿足不斷成長的商業需求，同時確保在整個預測期內產品品質穩定且供應充足。

預計到2025年，製藥企業將佔74.3%的市場。製藥企業仍然是市場需求的最大佔有率，因為他們擴大與專業的合約研發生產機構（CDMO）合作，以確保生產高品質的原料藥（API）、加快商業化進程並提高生產柔軟性。製藥公司越來越重視將複雜的胜肽類生產流程外包，以便能夠最佳化營運效率，同時專注於產品創新和臨床開發。預計在整個預測期內，對大規模生產、法規遵循和供應鏈韌性的投資增加將進一步增強來自此終端用戶領域的需求。

預計2025年，北美司Semaglutide和Tirzepatide原料藥契約製造服務日益成長的需求、不斷擴大的製藥外包活動以及先進的生產基礎設施，都將繼續支持該地區的市場成長。對生產技術、品管系統和法規遵從性的持續投資，進一步鞏固了北美在該領域的領先地位，並為在該地區運營的原料藥合約研發生產供應商創造了長期發展機會。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 全球肥胖和糖尿病負擔日益加重
    • GLP-1療法的商業性需求日益成長
    • 擴大胜肽的生產能力
    • 肽類原料藥（API）生產外包程度增加
  • 產業潛在風險與挑戰
    • 肽類藥物生產能力​​不足及供應限制
    • 胜肽合成的複雜性和原料的可獲得性
  • 市場機遇
    • 先進胜肽合成技術的引入
    • 開發治療肥胖症和代謝疾病的下一代療法
• 成長潛力分析
• 技術展望
  • 最新科技趨勢
  • 新興技術
• 監理情勢
• 波特的分析
• PESTLE分析
• 人工智慧和生成式人工智慧對市場的影響
• 投資與資金籌措分析
• 未來市場趨勢

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估算與預測：依API分類，2022-2035年

• Semaglutide
• Tirzepatide

第6章 市場估計與預測：依合成技術分類，2022-2035年

• 固相胜肽合成（SPPS）
• 液相肽合成（LPPS）
• 混合技術
• 其他合成技術

第7章 市場估計與預測：依服務類型分類，2022-2035年

• 契約製造
• 合約開發
• 分析和品管服務
• 監管和合規支持
• 其他服務

第8章 市場估算與預測：依企業規模分類，2022-2035年

• 臨床規模生產
• 商業規模生產

第9章 市場估計與預測：依最終用途分類，2022-2035年

• 製藥公司
• 生技公司
• 研究機構和學術中心

第10章 市場估價與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • UAE

第11章：公司簡介

• AmbioPharm
• Asymchem Laboratories
• Bachem
• BCN Peptides
• Catalent
• CordenPharma
• CPC Scientific
• Lonza
• PolyPeptide Group
• WuXi STA（WuXi TIDES）
• CSBio
• Curia
• GenScript

The Global Semaglutide and Tirzepatide API CDMO Market was valued at USD 1.5 billion in 2025 and is estimated to grow at a CAGR of 15.2% to reach USD 6.7 billion by 2035.

The market is witnessing rapid expansion due to the increasing global demand for peptide-based therapeutics and the growing commercialization of advanced treatments for chronic metabolic disorders. Raising outsourcing of active pharmaceutical ingredient (API) manufacturing to specialized contract development and manufacturing organizations (CDMOs) is creating significant growth opportunities for industry participants. Pharmaceutical companies are increasingly relying on experienced manufacturing partners to enhance production capacity, optimize costs, accelerate product development timelines, and ensure regulatory compliance. Growing investments in peptide synthesis technologies, process optimization, and large-scale manufacturing infrastructure are further supporting market expansion. In addition, the rising prevalence of chronic diseases, expanding biologics pipeline, and increasing focus on high-quality pharmaceutical manufacturing continue to strengthen demand for specialized API production services. Continuous technological advancements in peptide manufacturing, quality assurance, and process scalability are enabling CDMOs to meet evolving customer requirements. As pharmaceutical innovation continues to accelerate globally, the Semaglutide and Tirzepatide API CDMO market is expected to maintain strong growth throughout the forecast period.

The semaglutide segment held a 58.7% share in 2025 and is forecast to grow at a 14.8% CAGR during 2026 - 2035. Its market leadership is supported by widespread commercial adoption, a well-established global manufacturing ecosystem, and increasing demand for therapies targeting metabolic health. Continued growth in patient adoption, expanding production requirements, and increasing manufacturing outsourcing are strengthening demand for semaglutide API development and manufacturing services. CDMOs are investing in advanced peptide synthesis technologies, production capacity expansion, and process optimization to support rising commercial demand while ensuring consistent product quality and reliable supply throughout the forecast period.

The pharmaceutical manufacturers segment recorded a 74.3% share in 2025. Pharmaceutical manufacturers continue to account for the largest share of market demand as they increasingly partner with specialized CDMOs to secure high-quality API production, accelerate commercialization timelines, and improve manufacturing flexibility. Growing focus on outsourcing complex peptide manufacturing processes allows pharmaceutical companies to optimize operational efficiency while concentrating on product innovation and clinical development. Increasing investments in large-scale production, regulatory compliance, and supply chain resilience are expected to further strengthen demand from this end-user segment throughout the forecast period.

North America Semaglutide and Tirzepatide API CDMO Market captured a 39.1% share in 2025. The region continues to benefit from a strong pharmaceutical manufacturing base, advanced biopharmaceutical research capabilities, and increasing investments in peptide drug development. Rising demand for specialized contract manufacturing services, expanding pharmaceutical outsourcing activities, and the presence of advanced manufacturing infrastructure continue to support regional market growth. Continuous investments in production technologies, quality management systems, and regulatory compliance further strengthen North America's leadership while creating long-term opportunities for API CDMO providers operating across the region.

Major companies operating in the global semaglutide and tirzepatide api cdmo market include Lonza, WuXi STA (WuXi TIDES), Bachem, Catalent, PolyPeptide Group, CordenPharma, Asymchem Laboratories, AmbioPharm, Curia, CPC Scientific, BCN Peptides, GenScript, and CSBio. Companies operating in the global semaglutide and tirzepatide api cdmo market are strengthening their competitive position through strategic investments in manufacturing capacity, peptide synthesis technologies, and process innovation. Leading CDMOs are expanding production facilities to accommodate increasing commercial demand while enhancing operational efficiency and product quality. Manufacturers are investing heavily in research and development to improve manufacturing scalability, process optimization, and regulatory compliance. Strategic collaborations with pharmaceutical companies, long-term manufacturing agreements, and expansion of global production networks are helping businesses strengthen customer relationships and secure recurring revenue. Companies are also enhancing quality assurance systems, adopting advanced automation technologies, and expanding specialized peptide manufacturing capabilities to improve competitiveness. Continuous emphasis on technological advancement, operational excellence, regulatory expertise, and reliable supply chain management enables market participants to reinforce their market presence and sustain long-term growth in the global semaglutide and tirzepatide api cdmo market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Business trends
  • 2.2.2 API trends
  • 2.2.3 Synthesis technology trends
  • 2.2.4 Service type trends
  • 2.2.5 Scale of operation trends
  • 2.2.6 End use trends
  • 2.2.7 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing global obesity and diabetes burden
    • 3.2.1.2 Rising commercial demand for GLP-1 therapies
    • 3.2.1.3 Expansion of peptide manufacturing capacity
    • 3.2.1.4 Increasing outsourcing of peptide API production
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited peptide manufacturing capacity and supply constraints
    • 3.2.2.2 Complexity of peptide synthesis and raw material availability
  • 3.2.3 Market opportunities
    • 3.2.3.1 Adoption of advanced peptide synthesis technologies
    • 3.2.3.2 Expansion into next-generation obesity and metabolic therapies
• 3.3 Growth potential analysis
• 3.4 Technology landscape (Driven by primary research)
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Regulatory landscape (Driven by primary research)
  • 3.5.1 North America
  • 3.5.2 Europe
  • 3.5.3 Asia Pacific
  • 3.5.4 Latin America
  • 3.5.5 Middle East and Africa
• 3.6 Porter’s analysis
• 3.7 PESTEL analysis
• 3.8 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.9 Investment & funding analysis
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis (Driven by primary research)
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By API, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Semaglutide
• 5.3 Tirzepatide

Chapter 6 Market Estimates and Forecast, By Synthesis Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Solid-phase peptide synthesis (SPPS)
• 6.3 Liquid-phase peptide synthesis (LPPS)
• 6.4 Hybrid technology
• 6.5 Other synthesis technologies

Chapter 7 Market Estimates and Forecast, By Service Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Contract manufacturing
• 7.3 Contract development
• 7.4 Analytical & quality control services
• 7.5 Regulatory & compliance support
• 7.6 Other services

Chapter 8 Market Estimates and Forecast, By Scale of Operation, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Clinical-scale manufacturing
• 8.3 Commercial-scale manufacturing

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical manufacturers
• 9.3 Biotechnology companies
• 9.4 Research institutions & academic centers

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AmbioPharm
• 11.2 Asymchem Laboratories
• 11.3 Bachem
• 11.4 BCN Peptides
• 11.5 Catalent
• 11.6 CordenPharma
• 11.7 CPC Scientific
• 11.8 Lonza
• 11.9 PolyPeptide Group
• 11.10 WuXi STA (WuXi TIDES)
• 11.11 CSBio
• 11.12 Curia
• 11.13 GenScript